BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34476808)

  • 21. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
    Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
    Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
    Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
    Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
    Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
    Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
    Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
    Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Chatterjee G; Patkar N
    Br J Haematol; 2023 Feb; 200(3):277-279. PubMed ID: 36282207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Lebecque B; Besombes J; Dannus LT; De Antonio M; Cacheux V; Grèze V; Montagnon V; Veronese L; Tchirkov A; Tournilhac O; Berger MG; Veyrat-Masson R
    Br J Haematol; 2024 May; 204(5):1872-1881. PubMed ID: 38432068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
    Soh KT; Wallace PK
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
    Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
    Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
    Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
    Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
    Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
    Das N; Gupta R; Gupta SK; Bakhshi S; Seth R; Kumar C; Rai S; Singh S; Prajapati VK; Gogia A; Sahoo RK; Sharma A; Kumar L
    Ann Hematol; 2021 Oct; 100(10):2487-2500. PubMed ID: 34236495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
    Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
    Chen X; Gao Q; Roshal M; Cherian S
    Cytometry B Clin Cytom; 2023 May; 104(3):205-223. PubMed ID: 36683279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.